Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 08 2023
18 08 2023
Historique:
received:
12
03
2023
accepted:
13
08
2023
medline:
21
8
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab as first line therapy. This EAP was later discontinued when the IMpassion131 trial read out with negative results. We performed a retrospective multicentric analysis in patients who were prospectively enrolled in the French EAP. Efficacy and toxicity data were obtained on 64 patients treated from August 2019 to August 2020 in 10 French cancer centers. Median progression-free survival (PFS) and overall survival (OS) were 4.1 months (95% CI [3.0-5.8]) and 17.9 months (95% CI [12.4-NR]), respectively. The 6-months PFS rate was 28% (95% CI [16-40%]) (N = 18/64), while N = 33/64 patients (52%, 95% CI [38-63%]) experienced a tumor response. Exploratory subgroup analyses retrieved that corticosteroid use at inclusion in the EAP, before treatment initiation, was the only independent unfavorable prognostic factor for PFS (HR 2.7, 95% CI [1.3-5.6]). No new safety signal was observed. This real-life study, unique by its setting (EAP granted by anticipation and later withdrawn), suggests atezolizumab and paclitaxel has a limited efficacy in PD-L1-positive aTNBC, especially in patients receiving corticosteroids as comedication before treatment start.
Identifiants
pubmed: 37596388
doi: 10.1038/s41598-023-40569-9
pii: 10.1038/s41598-023-40569-9
pmc: PMC10439112
doi:
Substances chimiques
atezolizumab
52CMI0WC3Y
Paclitaxel
P88XT4IS4D
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13427Informations de copyright
© 2023. Springer Nature Limited.
Références
Adams, S., Goldstein, L. J., Sparano, J. A., Demaria, S. & Badve, S. S. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). OncoImmunology 4, e985930 (2015).
doi: 10.4161/2162402X.2014.985930
pubmed: 26405612
pmcid: 4570112
Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2, 361–370 (2014).
doi: 10.1158/2326-6066.CIR-13-0127
pubmed: 24764583
pmcid: 4000553
Adams, S. et al. Atezolizumab Plus nab-Paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: A phase 1b clinical trial. JAMA Oncol. 5, 334–342 (2019).
doi: 10.1001/jamaoncol.2018.5152
pubmed: 30347025
Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol. 5, 74–82 (2019).
doi: 10.1001/jamaoncol.2018.4224
pubmed: 30242306
Schmid, P. et al. IMPASSION-130—Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
doi: 10.1056/NEJMoa1809615
pubmed: 30345906
Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44–59 (2020).
doi: 10.1016/S1470-2045(19)30689-8
pubmed: 31786121
Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983–993 (2021).
doi: 10.1016/j.annonc.2021.05.355
pubmed: 34272041
Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol. 32, 994–1004 (2021).
doi: 10.1016/j.annonc.2021.05.801
pubmed: 34219000
Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529–1541 (2021).
doi: 10.1056/NEJMoa2028485
pubmed: 33882206
Garant, A. et al. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. Crit. Rev. Oncol. Hematol. 120, 86–92 (2017).
doi: 10.1016/j.critrevonc.2017.10.009
pubmed: 29198341
Chasset, F. et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: Negative impact of baseline corticosteroids. Eur. J. Dermatol. 25, 36–44 (2015).
doi: 10.1684/ejd.2014.2471
pubmed: 25500362
Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459–465 (2012).
doi: 10.1016/S1470-2045(12)70090-6
pubmed: 22456429
Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872–2878 (2018).
doi: 10.1200/JCO.2018.79.0006
pubmed: 30125216
Franzoi, M. A. & de Azambuja, E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials—How to explain different results?. ESMO Open 5, e001112 (2020).
doi: 10.1136/esmoopen-2020-001112
pubmed: 33214229
pmcid: 7678394
Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817–1828 (2020).
doi: 10.1016/S0140-6736(20)32531-9
pubmed: 33278935
Røssevold, A. H. et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: The randomized, double-blind phase 2b ALICE trial. Nat. Med. 28, 2573–2583 (2022).
doi: 10.1038/s41591-022-02126-1
pubmed: 36482103
pmcid: 9800277